258 related articles for article (PubMed ID: 36380859)
41. Circulating tumor cells as promising novel biomarkers in solid cancers.
Lianidou ES; Strati A; Markou A
Crit Rev Clin Lab Sci; 2014 Jun; 51(3):160-71. PubMed ID: 24641350
[TBL] [Abstract][Full Text] [Related]
42. Introduction - Biology of Breast Cancer Metastasis and Importance of the Analysis of CTCs.
Piñeiro R
Adv Exp Med Biol; 2020; 1220():1-10. PubMed ID: 32304076
[TBL] [Abstract][Full Text] [Related]
43. Liquid Biopsies: Flowing Biomarkers.
Hyenne V; Goetz JG; Osmani N
Adv Exp Med Biol; 2022; 1379():341-368. PubMed ID: 35760999
[TBL] [Abstract][Full Text] [Related]
44. Comparison of the HER2, estrogen and progesterone receptor expression profile of primary tumor, metastases and circulating tumor cells in metastatic breast cancer patients.
Aktas B; Kasimir-Bauer S; Müller V; Janni W; Fehm T; Wallwiener D; Pantel K; Tewes M;
BMC Cancer; 2016 Jul; 16():522. PubMed ID: 27456970
[TBL] [Abstract][Full Text] [Related]
45. Possible role of circulating tumor cells in early detection of lung cancer.
Poggiana C; Rossi E; Zamarchi R
J Thorac Dis; 2020 Jul; 12(7):3821-3835. PubMed ID: 32802464
[TBL] [Abstract][Full Text] [Related]
46. Lymph Liquid Biopsy for Detection of Cancer Stem Cells.
Han M; Watts JA; Jamshidi-Parsian A; Nadeem U; Siegel ER; Zharov VP; Galanzha EI
Cytometry A; 2021 May; 99(5):496-502. PubMed ID: 32869909
[TBL] [Abstract][Full Text] [Related]
47. Extracellular vesicles for personalized therapy decision support in advanced metastatic cancers and its potential impact for prostate cancer.
Soekmadji C; Corcoran NM; Oleinikova I; Jovanovic L; ; Ramm GA; Nelson CC; Jenster G; Russell PJ
Prostate; 2017 Oct; 77(14):1416-1423. PubMed ID: 28856701
[TBL] [Abstract][Full Text] [Related]
48. Cell Free DNA as an Evolving Liquid Biopsy Biomarker for Initial Diagnosis and Therapeutic Nursing in Cancer- An Evolving Aspect in Medical Biotechnology.
Ray SK; Mukherjee S
Curr Pharm Biotechnol; 2022; 23(1):112-122. PubMed ID: 33308128
[TBL] [Abstract][Full Text] [Related]
49. Liquid biopsy and their application progress in head and neck cancer: focus on biomarkers CTCs, cfDNA, ctDNA and EVs.
Meng Y; Bian L; Zhang M; Bo F; Lu X; Li D
Biomark Med; 2020 Oct; 14(14):1393-1404. PubMed ID: 33073579
[TBL] [Abstract][Full Text] [Related]
50. Clinical relevance of circulating molecules in cancer: focus on gastrointestinal stromal tumors.
Ravegnini G; Sammarini G; Serrano C; Nannini M; Pantaleo MA; Hrelia P; Angelini S
Ther Adv Med Oncol; 2019; 11():1758835919831902. PubMed ID: 30854029
[TBL] [Abstract][Full Text] [Related]
51. The double agents in liquid biopsy: promoter and informant biomarkers of early metastases in breast cancer.
Richard V; Davey MG; Annuk H; Miller N; Kerin MJ
Mol Cancer; 2022 Apr; 21(1):95. PubMed ID: 35379239
[TBL] [Abstract][Full Text] [Related]
52.
Mastoraki S; Strati A; Tzanikou E; Chimonidou M; Politaki E; Voutsina A; Psyrri A; Georgoulias V; Lianidou E
Clin Cancer Res; 2018 Mar; 24(6):1500-1510. PubMed ID: 29284708
[No Abstract] [Full Text] [Related]
53. Evolutionary model of brain tumor circulating cells: Cellular galaxy.
Mehdipour P; Javan F; Jouibari MF; Khaleghi M; Mehrazin M
World J Clin Oncol; 2021 Jan; 12(1):13-30. PubMed ID: 33552936
[TBL] [Abstract][Full Text] [Related]
54. Combinatorial Power of cfDNA, CTCs and EVs in Oncology.
Keup C; Kimmig R; Kasimir-Bauer S
Diagnostics (Basel); 2022 Mar; 12(4):. PubMed ID: 35453918
[TBL] [Abstract][Full Text] [Related]
55. Liquid biopsies.
Lianidou E; Pantel K
Genes Chromosomes Cancer; 2019 Apr; 58(4):219-232. PubMed ID: 30382599
[TBL] [Abstract][Full Text] [Related]
56. The potential of liquid biopsy in the management of cancer patients.
Markou A; Tzanikou E; Lianidou E
Semin Cancer Biol; 2022 Sep; 84():69-79. PubMed ID: 35331850
[TBL] [Abstract][Full Text] [Related]
57. Single cell mutational analysis of PIK3CA in circulating tumor cells and metastases in breast cancer reveals heterogeneity, discordance, and mutation persistence in cultured disseminated tumor cells from bone marrow.
Deng G; Krishnakumar S; Powell AA; Zhang H; Mindrinos MN; Telli ML; Davis RW; Jeffrey SS
BMC Cancer; 2014 Jun; 14():456. PubMed ID: 24947048
[TBL] [Abstract][Full Text] [Related]
58. Recent Advances in Device Engineering and Computational Analysis for Characterization of Cell-Released Cancer Biomarkers.
Abouali H; Hosseini SA; Purcell E; Nagrath S; Poudineh M
Cancers (Basel); 2022 Jan; 14(2):. PubMed ID: 35053452
[TBL] [Abstract][Full Text] [Related]
59. Clinical significance of circulating tumor cells (CTCs) with respect to optimal cut-off value and tumor markers in advanced/metastatic breast cancer.
Shiomi-Mouri Y; Kousaka J; Ando T; Tetsuka R; Nakano S; Yoshida M; Fujii K; Akizuki M; Imai T; Fukutomi T; Kobayashi K
Breast Cancer; 2016 Jan; 23(1):120-127. PubMed ID: 24906662
[TBL] [Abstract][Full Text] [Related]
60. Challenges and unanswered questions for the next decade of circulating tumour cell research in lung cancer.
Mohan S; Chemi F; Brady G
Transl Lung Cancer Res; 2017 Aug; 6(4):454-472. PubMed ID: 28904889
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
